产品
编 号：F156520
分子式：C22H23F3N4O4
分子量：464.44
分子式：C22H23F3N4O4
分子量：464.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1421438-81-4
产品详情
生物活性：
Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested.
体内研究：
Crenigacestat (8 mg/kg, oral gavage three times a week) resulted in significantly increases survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC.Animal Model:CCRCC xenografts were established in NOD-scid IL2R null mice with subcutaneous implantation using the 769-P cell line.
Dosage:8 mg/kg.
Administration:Oral gavage three times a week.
Result:Resulted in increased overall survival when compared with vehicle control in CCRCC xenografts.
体外研究：
Crenigacestat (100 nM) exhibits anti-cancer activity in K07074 cells (a primary mouse liver tumor cell line).Crenigacestat (LY3039478) decreases expression of Myc and cyclin A1 (part of the NOTCH-driven proliferative signature) in murine and human model systems. Crenigacestat (LY3039478) treatment also leads to G0/G1 cell cycle arrest in CCRCC cells.
Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested.
体内研究：
Crenigacestat (8 mg/kg, oral gavage three times a week) resulted in significantly increases survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC.Animal Model:CCRCC xenografts were established in NOD-scid IL2R null mice with subcutaneous implantation using the 769-P cell line.
Dosage:8 mg/kg.
Administration:Oral gavage three times a week.
Result:Resulted in increased overall survival when compared with vehicle control in CCRCC xenografts.
体外研究：
Crenigacestat (100 nM) exhibits anti-cancer activity in K07074 cells (a primary mouse liver tumor cell line).Crenigacestat (LY3039478) decreases expression of Myc and cyclin A1 (part of the NOTCH-driven proliferative signature) in murine and human model systems. Crenigacestat (LY3039478) treatment also leads to G0/G1 cell cycle arrest in CCRCC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备